Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

BACKGROUND: Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven. Antiviral combinations have not been systematically studied. We aimed to evaluate the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, David M., Brown, Li-An K., Chowdhury, Kashfia, Davey, Stephanie, Yee, Philip, Ikeji, Felicia, Ndoutoumou, Amalia, Shah, Divya, Lennon, Alexander, Rai, Abhulya, Agyeman, Akosua A., Checkley, Anna, Longley, Nicola, Dehbi, Hakim-Moulay, Freemantle, Nick, Breuer, Judith, Standing, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629589/
https://www.ncbi.nlm.nih.gov/pubmed/36260627
http://dx.doi.org/10.1371/journal.pmed.1004120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629589/
https://www.ncbi.nlm.nih.gov/pubmed/36260627
http://dx.doi.org/10.1371/journal.pmed.1004120

Ejemplares similares